Shanghai, China – November 16, 2025 — MicroPort^® CardioFlow (02160.HK) has reached a critical milestone in its international expansion, with over 1,000 commercial implantations of its VitaFlow^® TAVI systems performed outside of China. Nearly 30% of these procedures took place in Europe, the achievement signals a critical breakthrough in the company's globalization strategy and a transition into high-quality, large-scale international growth.

The company's flagship second-generation system, VitaFlow Liberty^®, is now available in 32 countries, with rapid uptake in Europe, Latin America, and Asia. As of October 2025, the system has been adopted by 800+ hospitals and supported more than 17,000 procedures worldwide.

This milestone reflects the success of MicroPort^® CardioFlow's dual-channel global strategy, combining direct operations with localized distributor networks, and backed by strong clinical evidence and continuous product innovation.

As part of a broader pipeline, MicroPort^® CardioFlow is also advancing multiple next-generation heart valve and structural heart solutions across TAVI, TMVR, TTVR, and stroke prevention, reinforcing its position as a global player in structural heart innovation.